Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Jun 27 2024

Full Issue

Health Conditions Decide Which Elders Under 75 Need RSV Vaccine, CDC Says

Although all Americans 75 and older are recommended to get the shot, only those in the younger group with chronic heart or lung disease or other high-risk factors would need it, officials concluded.

The New York Times: Federal Officials Revise Recommendations For R.S.V. Vaccine 

In an unusual move, federal health officials revised their recommendations for who should receive the vaccine against the respiratory syncytial virus. Among Americans aged 60 to 74, only those with certain health conditions need to receive the shots, the CDC concluded. (Mandavilli, 6/26)

Reuters: Moderna Says Its RSV Shot Is 50% Effective Across A Second Season

Moderna Inc. respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday. In their clinical trials, GSK's RSV vaccine Arexvy was 78% effective in preventing severe RSV over a second year and Pfizer's was 78% effective through a second RSV season. (6/26)

On bird flu —

CIDRAP: USDA Confirms More H5N1 Detections In Dairy Herds And Cats

The US Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed H5N1 avian influenza in three more dairy herds, two in Colorado and one in Iowa, raising its number of affected herds to 129 in 12 states. APHIS today added reports of nine more H5N1 detections in mammals across four states, of which five were domestic cats. The infected cats were from Minnesota (Kandiyohi County) and Texas (Hartley County). Other detections involved raccoons from Michigan and New Mexico, a striped skunk for New Mexico, and a red fox from Minnesota. The group also added eight more detections in wild birds, including five bald eagles from Iowa, New Jersey, and Virginia and three agency-harvested birds from New Mexico. (Schnirring, 6/26)

Stat: Mike Leavitt Interview On Bird Flu Response 

Mike Leavitt is in the small club of government officials who’ve led an avian flu response. The experience is still fresh in his mind nearly two decades later. When he first heard about the avian flu outbreak in 2005, he had been secretary of health and human services in George W. Bush’s administration for just a couple of months. (Zhang, 6/27)

On covid and mpox —

CIDRAP: New Study Aims To Define Long COVID Through Phenotypes Of Patients

A new study in the Journal of Infectious Diseases uses data from 1,988 SARS-CoV-2–positive US Military Health System beneficiaries to define the characteristics and clinical patterns observed in patients with long COVID, or post-COVID condition (PCC), grouping patients into three phenotypes based on clusters of symptoms. (Soucheray, 6/26)

USA Today: Mpox In Africa: WHO Urges More Awareness; Deadly Strain Reported

The World Health Organization urged greater attention to mpox cases Tuesday as independent scientists raised concerns that a more deadly version of the virus is circulating in the Democratic Republic of Congo. "There is a critical need to address the recent surge in mpox cases in Africa," Rosamund Lewis, the WHO's technical lead for mpox, said to reporters in a briefing note, as reported by Reuters. (Powel and Forbes, 6/26)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF